Abstract
Passive serotherapy can confer immediate protection against microbial infection, but methods to rapidly generate human neutralizing monoclonal antibodies are not yet available. We have developed an improved method for Epstein-Barr virus transformation of human B cells. We used this method to analyze the memory repertoire of a patient who recovered from severe acute respiratory syndrome coronavirus (SARS-CoV) infection and to isolate monoclonal antibodies specific for different viral proteins, including 35 antibodies with in vitro neutralizing activity ranging from 10−8M to 10−11M. One such antibody confers protection in vivo in a mouse model of SARS-CoV infection. These results show that it is possible to interrogate the memory repertoire of immune donors to rapidly and efficiently isolate neutralizing antibodies that have been selected in the course of natural infection.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
References
Behring, E. & Kitasato, S. [On the development of immunity to diphtheria and tetanus in animals]. Dtsch Med. Wochenschr. 90, 2183 (1965).
Keller, M.A. & Stiehm, E.R. Passive immunity in prevention and treatment of infectious diseases. Clin. Microbiol. Rev. 13, 602–614 (2000).
Kohler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495–497 (1975).
Steinitz, M., Klein, G., Koskimies, S. & Makel, O. EB virus-induced B lymphocyte cell lines producing specific antibody. Nature 269, 420–422 (1977).
Kozbor, D. & Roder, J.C. Requirements for the establishment of high-titered human monoclonal antibodies against tetanus toxoid using the Epstein-Barr virus technique. J. Immunol. 127, 1275–1280 (1981).
Lanzavecchia, A. Antigen-specific interaction between T and B cells. Nature 314, 537–539 (1985).
Kozbor, D., Roder, J.C., Chang, T.H., Steplewski, Z. & Koprowski, H. Human anti-tetanus toxoid monoclonal antibody secreted by EBV-transformed human B cells fused with murine myeloma. Hybridoma 1, 323–328 (1982).
Karpas, A., Dremucheva, A. & Czepulkowski, B.H. A human myeloma cell line suitable for the generation of human monoclonal antibodies. Proc. Natl. Acad. Sci. USA 98, 1799–1804 (2001).
Jones, P.T., Dear, P.H., Foote, J., Neuberger, M.S. & Winter, G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321, 522–525 (1986).
McCafferty, J., Griffiths, A.D., Winter, G. & Chiswell, D.J. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348, 552–554 (1990).
Green, L.L. Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J. Immunol. Methods 231, 11–23 (1999).
Brekke, O.H. & Sandlie, I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat. Rev. Drug Discov. 2, 52–62 (2003).
Johnson, S. et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 176, 1215–1224 (1997).
Drosten, C. et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348, 1967–1976 (2003).
Ksiazek, T.G. et al. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348, 1953–1966 (2003).
Rota, P.A. et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300, 1394–1399 (2003).
Fouchier, R.A. et al. Aetiology: Koch's postulates fulfilled for SARS virus. Nature 423, 240 (2003).
Poutanen, S.M. et al. Identification of severe acute respiratory syndrome in Canada. N. Engl. J. Med. 348, 1995–2005 (2003).
Lee, N. et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N. Engl. J. Med. 348, 1986–1994 (2003).
Donnelly, C.A. et al. Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. Lancet 361, 1761–1766 (2003).
Giachino, C., Padovan, E. & Lanzavecchia, A. κ+λ+ dual receptor B cells are present in the human peripheral repertoire. J. Exp. Med. 181, 1245–1250 (1995).
Hartmann, G. & Krieg, A.M. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J. Immunol. 164, 944–953 (2000).
Bernasconi, N.L., Traggiai, E. & Lanzavecchia, A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298, 2199–2202 (2002).
Subbarao, K. et al. Prior infection and passive transfer of neutralizing antibody protect mice from subsequent infection with SARS coronavirus. J. Virol. 78, 3572–3577 (2004).
Gebauer, F. et al. Residues involved in the antigenic sites of transmissible gastroenteritis coronavirus S glycoprotein. Virology 183, 225–238 (1991).
Graham, B.S., Perkins, M.D., Wright, P.F. & Karzon, D.T. Primary respiratory syncytial virus infection in mice. J. Med. Virol. 26, 153–162 (1988).
Stack, A.M. et al. Primary respiratory syncytial virus infection: pathology, immune response, and evaluation of vaccine challenge strains in a new mouse model. Vaccine 18, 1412–1418 (2000).
Becker, S., Feldmann, H., Will, C. & Slenczka, W. Evidence for occurrence of filovirus antibodies in humans and imported monkeys: do subclinical filovirus infections occur worldwide? Med. Microbiol. Immunol. (Berl.) 181, 43–55 (1992).
Karber, G. 50% end-point calculation. Arch. Exp. Pathol. Pharmak. 162, 480–483 (1931).
Perri, S. et al. An alphavirus replicon particle chimera derived from Venezuelan equine encephalitis and Sindbis viruses is a potent gene-based vaccine delivery vector. J. Virol. 77, 10394–10403 (2003).
Acknowledgements
We thank J. McAuliffe and L. Vogel from the Laboratory of Infectious Diseases, NIAID, for expert assistance in performing the animal studies. We thank I. Giacchetto for expert technical assistance and F. Sallusto for critical reading and comments. A.L. is supported by the Helmut Horten Foundation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The Institute for Research in Biomedicine has a patent application that covers the method described in this article.
Supplementary information
Rights and permissions
About this article
Cite this article
Traggiai, E., Becker, S., Subbarao, K. et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 10, 871–875 (2004). https://doi.org/10.1038/nm1080
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/nm1080
This article is cited by
-
Clonal structure, stability and dynamics of human memory B cells and circulating plasmablasts
Nature Immunology (2022)
-
Anti-viral and pro-inflammatory functions of Toll-like receptors during gamma-herpesvirus infections
Virology Journal (2021)
-
Antibodies, epicenter of SARS-CoV-2 immunology
Cell Death & Differentiation (2021)
-
Generation and Characterization of a Nanobody Against SARS-CoV
Virologica Sinica (2021)
-
Development of therapeutic antibodies for the treatment of diseases
Journal of Biomedical Science (2020)